Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion type Assertion NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_head.
- NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion description "[The long-term goal of human gene therapy for sickle cell disease then consists of constructing optimally safe and efficient retroviral packaging lines as well as retroviral vectors containing the human beta-globin gene and selectable markers such as the neoR gene.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_provenance.
- NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion evidence source_evidence_literature NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_provenance.
- NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion SIO_000772 2672970 NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_provenance.
- NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion wasDerivedFrom befree-2016 NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_provenance.
- NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_assertion wasGeneratedBy ECO_0000203 NP1295872.RATWYeaFOt9Xtzg7shtxIx6YC6Oq5aEfe7yNWm-5xa0Mo130_provenance.